90-day fills for chronic hepatitis B treatments increased patient adherence

Being prescribed a 90-day or a “mixed duration” supply of entecavir or tenofovir disoproxil fumarate was associated with higher fill rates among commercially insured patients with chronic hepatitis B, researchers found.“There has been a lot of important research on barriers that prevent patients with chronic hepatitis B (CHB) from receiving the care they need,” Jonathan D. Alpern, MD, assistant professor of medicine at the University of Minnesota, told Healio. “However, less is known about barriers to medication adherence in this population.”Alpern addedRead More